| |
|
Primary lung cancer group |
|
Control group |
|
| Total number |
|
226 |
|
103 |
|
| Age (years) |
|
69±9 (39-87) |
|
62±15 (23-91) |
<0.0001* |
| Sex |
males |
153 |
|
60 |
0.107** |
| |
females |
73 |
|
43 |
|
| Serum KL-6 level (U/ml) |
|
375±232 (130-1676) |
|
296±177 (133-1660) |
0.003* |
| Histology |
adenocarcinoma |
134 |
|
|
|
| |
squamous cell carcinoma |
53 |
|
|
|
| |
adenosquamous carcinoma |
9 |
|
|
|
| |
large cell carcinoma |
13 |
|
|
|
| |
small cell carcinoma |
10 |
|
|
|
| |
pleomorphic carcinoma |
5 |
|
|
|
| |
unknown |
2 |
|
Diseases of the control group |
| Tumour size |
|
|
3.3±2.0 (0.4-11.4) cm |
benign mediastinal tumour |
21 |
| TNM |
T |
1a |
69 |
lung abscess |
1 |
| |
|
1b |
54 |
scar and old inflammation |
31 |
| |
|
2a |
57 |
tuberculosis |
4 |
| |
|
2b |
19 |
atypical mycobacteriosis |
11 |
| |
|
3 |
22 |
mycotic infection |
5 |
| |
|
4 |
5 |
benign pulmonary tumour |
3 |
| |
N |
0 |
168 |
sarcoidosis |
7 |
| |
|
1 |
12 |
pleural infection |
3 |
| |
|
2 |
36 |
myasthenia gravis |
2 |
| |
|
3 |
10 |
COPD |
5 |
| |
M |
0 |
210 |
congenital lung disease |
3 |
| |
|
1a |
6 |
pneumothorax |
2 |
| |
|
1b |
10 |
chest trauma |
1 |
| Stage |
IA |
|
103 |
benign chest wall tumour |
1 |
| |
IB |
|
34 |
benign pleural tumour |
1 |
| |
IIA |
|
21 |
benign tracheal tumour |
1 |
| |
IIB |
|
12 |
silicosis |
1 |
| |
IIIA |
|
28 |
|
|
| |
IIIB |
|
12 |
|
|
| |
IV |
|
16 |
|
|
Values are mean ± SD (range) or number
* p values indicate the results of ANOVA; ** p values indicate the result of a chi-square test. |
